Do analysts rate ALGS or MENS?

Aligos Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 581.42%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aligos Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ALGS or MENS?

Jyong Biotech has lower revenue, but higher earnings than Aligos Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aligos Therapeutics $2.19M 15.97 -$24.19M -$8.69 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Do analysts prefer THAR or ALGS?

Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 581.42%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Is ALGS or ENGN more profitable?

enGene has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. enGene's return on equity of -56.06% beat Aligos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aligos Therapeutics -1,919.68% -139.47% -90.88% enGene N/A -56.06% -45.64%

Aligos Therapeutics (ALGS) Competitors

$5.65 -0.04 (-0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$5.58 -0.07 (-1.31%)

As of 07:09 PM Eastern

Compare

ALGS vs. MENS, THAR, CRDL, ENGN, and IFRX

Should you buy Aligos Therapeutics stock or one of its competitors? MarketBeat compares Aligos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aligos Therapeutics include Jyong Biotech (MENS), Tharimmune (THAR), Cardiol Therapeutics (CRDL), enGene (ENGN), and InflaRx (IFRX). These companies are all part of the "pharmaceutical products" industry.

How does Aligos Therapeutics compare to Jyong Biotech?

Aligos Therapeutics (NASDAQ:ALGS) and Jyong Biotech (NASDAQ:MENS) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

60.4% of Aligos Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Aligos Therapeutics' average media sentiment score of 0.00 equaled Jyong Biotech'saverage media sentiment score.

Company	Overall Sentiment
Aligos Therapeutics	Neutral
Jyong Biotech	Neutral

Aligos Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 581.42%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aligos Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jyong Biotech has lower revenue, but higher earnings than Aligos Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.97	-$24.19M	-$8.69	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Jyong Biotech has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Jyong Biotech's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Jyong Biotech	N/A	N/A	N/A

Summary

Aligos Therapeutics beats Jyong Biotech on 7 of the 11 factors compared between the two stocks.

How does Aligos Therapeutics compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Tharimmune's average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score.

Company	Overall Sentiment
Tharimmune	Neutral
Aligos Therapeutics	Neutral

Tharimmune has higher earnings, but lower revenue than Aligos Therapeutics. Tharimmune is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Aligos Therapeutics	$2.19M	15.97	-$24.19M	-$8.69	N/A

Tharimmune has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

Tharimmune has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market.

Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 581.42%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Aligos Therapeutics beats Tharimmune on 11 of the 14 factors compared between the two stocks.

How does Aligos Therapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Cardiol Therapeutics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cardiol Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Aligos Therapeutics' return on equity of -139.47% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

Aligos Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Aligos Therapeutics	$2.19M	15.97	-$24.19M	-$8.69	N/A

Cardiol Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 709.52%. Aligos Therapeutics has a consensus price target of $38.50, indicating a potential upside of 581.42%. Given Cardiol Therapeutics' higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Aligos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Aligos Therapeutics. MarketBeat recorded 1 mentions for Cardiol Therapeutics and 0 mentions for Aligos Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Aligos Therapeutics	Neutral

Summary

Aligos Therapeutics beats Cardiol Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Aligos Therapeutics compare to enGene?

Aligos Therapeutics (NASDAQ:ALGS) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

enGene has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. enGene's return on equity of -56.06% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
enGene	N/A	-56.06%	-45.64%

In the previous week, enGene had 15 more articles in the media than Aligos Therapeutics. MarketBeat recorded 15 mentions for enGene and 0 mentions for Aligos Therapeutics. enGene's average media sentiment score of 0.23 beat Aligos Therapeutics' score of 0.00 indicating that enGene is being referred to more favorably in the news media.

Company	Overall Sentiment
Aligos Therapeutics	Neutral
enGene	Neutral

Aligos Therapeutics has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.97	-$24.19M	-$8.69	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aligos Therapeutics has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market. Comparatively, enGene has a beta of -0.3, indicating that its share price is 130% less volatile than the broader market.

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 581.42%. enGene has a consensus target price of $11.05, indicating a potential upside of 545.93%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Aligos Therapeutics is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Aligos Therapeutics and enGene tied by winning 8 of the 16 factors compared between the two stocks.

How does Aligos Therapeutics compare to InflaRx?

Aligos Therapeutics (NASDAQ:ALGS) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

In the previous week, Aligos Therapeutics' average media sentiment score of 0.00 equaled InflaRx'saverage media sentiment score.

Company	Overall Sentiment
Aligos Therapeutics	Neutral
InflaRx	Neutral

Aligos Therapeutics has higher revenue and earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.97	-$24.19M	-$8.69	N/A
InflaRx	$30K	4,650.66	-$51.63M	-$0.71	N/A

InflaRx has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. InflaRx's return on equity of -88.30% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
InflaRx	N/A	-88.30%	-65.77%

Aligos Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, InflaRx has a beta of 2.42, suggesting that its share price is 142% more volatile than the broader market.

Aligos Therapeutics currently has a consensus target price of $38.50, suggesting a potential upside of 581.42%. InflaRx has a consensus target price of $7.00, suggesting a potential upside of 262.69%. Given Aligos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Aligos Therapeutics and InflaRx tied by winning 7 of the 14 factors compared between the two stocks.

Get Aligos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALGS vs. The Competition

Export

Metric	Aligos Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$35.21M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-0.65	19.75	24.92	23.97
Price / Sales	15.97	329.42	528.81	109.59
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.65	8.29	10.79	6.50
Net Income	-$24.19M	$23.85M	$3.56B	$336.88M
7 Day Performance	13.23%	5.21%	1.67%	-0.22%
1 Month Performance	-1.91%	2.19%	0.43%	0.77%
1 Year Performance	-21.31%	60.99%	32.84%	31.57%

Aligos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALGS Aligos Therapeutics	2.8562 of 5 stars	$5.65 -0.7%	$38.50 +581.4%	-24.6%	$35.21M	$2.19M	N/A	90
MENS Jyong Biotech	N/A	$1.60 flat	N/A	N/A	$121.65M	N/A	N/A	31
THAR Tharimmune	N/A	$3.21 +3.9%	N/A	+150.0%	$121.11M	N/A	N/A	2	Gap Up
CRDL Cardiol Therapeutics	1.7859 of 5 stars	$1.05 flat	$8.50 +709.5%	-14.5%	$121.01M	N/A	N/A	20	News Coverage Positive News
ENGN enGene	3.7615 of 5 stars	$1.75 -1.1%	$12.50 +614.3%	-46.3%	$117.23M	N/A	N/A	31

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALGS) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aligos Therapeutics (ALGS) Competitors

ALGS vs. MENS, THAR, CRDL, ENGN, and IFRX

How does Aligos Therapeutics compare to Jyong Biotech?

Summary

How does Aligos Therapeutics compare to Tharimmune?

Summary

How does Aligos Therapeutics compare to Cardiol Therapeutics?

Summary

How does Aligos Therapeutics compare to enGene?

Summary

How does Aligos Therapeutics compare to InflaRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aligos Therapeutics (ALGS) Competitors

ALGS vs. MENS, THAR, CRDL, ENGN, and IFRX

How does Aligos Therapeutics compare to Jyong Biotech?

Do institutionals and insiders believe in ALGS or MENS?

Does the media prefer ALGS or MENS?

Do analysts rate ALGS or MENS?

Which has better valuation and earnings, ALGS or MENS?

Is ALGS or MENS more profitable?

Summary

How does Aligos Therapeutics compare to Tharimmune?

Do institutionals and insiders believe in THAR or ALGS?

Does the media refer more to THAR or ALGS?

Which has higher valuation and earnings, THAR or ALGS?

Is THAR or ALGS more profitable?

Which has more volatility & risk, THAR or ALGS?

Do analysts prefer THAR or ALGS?

Summary

How does Aligos Therapeutics compare to Cardiol Therapeutics?

Which has more risk and volatility, CRDL or ALGS?

Do institutionals & insiders believe in CRDL or ALGS?

Is CRDL or ALGS more profitable?

Which has stronger valuation & earnings, CRDL or ALGS?

Do analysts rate CRDL or ALGS?

Does the media favor CRDL or ALGS?

Summary

How does Aligos Therapeutics compare to enGene?

Is ALGS or ENGN more profitable?

Does the media prefer ALGS or ENGN?

Which has better valuation and earnings, ALGS or ENGN?

Do insiders and institutionals have more ownership in ALGS or ENGN?

Which has more volatility & risk, ALGS or ENGN?

Do analysts rate ALGS or ENGN?

Summary

How does Aligos Therapeutics compare to InflaRx?

Does the media prefer ALGS or IFRX?

Which has stronger earnings & valuation, ALGS or IFRX?

Is ALGS or IFRX more profitable?

Which has more volatility and risk, ALGS or IFRX?

Do analysts rate ALGS or IFRX?

Do insiders & institutionals hold more shares of ALGS or IFRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGS vs. The Competition

Aligos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools